



AACR Virtual Meeting  
**Advances in Malignant Lymphoma:  
Maximizing the Basic-Translational Interface for Clinical  
Application**  
*In cooperation with the International Conference on Malignant Lymphoma (ICML)*  
August 17–19, 2020 | Virtual Meeting

## **Monday, August 17**

---

### **Welcome and Opening Keynote Address**

10:30–11:15 a.m.

Channel 1

- |                  |  |
|------------------|--|
| 10:30–10:35 a.m. | Welcome and Keynote Introduction<br>Ari M. Melnick, Weill Cornell Medical College, New York, NY  |
| 10:35–11 a.m.    | <b>Rogue clones of self-reactive B cells with lymphoma driver mutations:<br/>A view of lymphoma precursors</b><br>Christopher Goodnow, Garvan Institute of Medical Research, Darlinghurst,<br>NSW, Australia |
| 11–11:15 a.m.    | Discussion / Q&A   |

### **Break**

11:15–11:30 a.m.

### **Session 1: Teaching T-Cells New Tricks: Why Immunotherapy Fails in Lymphoma and How Do We Fix It?**

*Moderator: Helen E. Heslop, Baylor College of Medicine, Houston, TX*

11:30 a.m.–1:05 p.m.

Channel 1

- |                  |   |
|------------------|---|
| 11:30–11:35 a.m. | Moderator Introduction  |
| 11:35–11:50 a.m. | <b>The bad guys of follicular lymphoma microenvironment: Putative<br/>impact on therapy failure?</b><br>Karin Tarte, Université de Rennes, Rennes, France |

- 11:50 a.m.–12:05 p.m. **Immune exhaustion and suppression in lymphoma**  
Stephen M. Ansell, Mayo Clinic College of Medicine, Rochester, MN
- 12:05–12:20 p.m. **Optimizing immunostimulatory antibodies for cancer immunotherapy**  
Mark Cragg, University of Southampton, Southampton, United Kingdom
- 12:20–12:35 p.m. **The immune cell microenvironment of classical Hodgkin lymphoma by single-cell analysis**  
Christian Steidl, BC Cancer, Vancouver, BC, Canada
- 12:35–1:05 p.m. Discussion / Q&A

### Break

1:05–1:20 p.m.

### Session 2: WHO vs. How? Changing Paradigms in Lymphoma Classification

*Moderator: Georg Lenz, University of Münster, Münster, Germany*

1:20–2:55 p.m.

Channel 1

- 1:20–1:25 p.m. Moderator Introduction
- 1:25–1:40 p.m. **Molecular classification of T-cell lymphomas**  
Keisuke Kataoka, National Cancer Center, Japan, Tokyo, Japan
- 1:40–1:55 p.m. **The role of gene expression in the classification of aggressive B-cell lymphoma**  
David W. Scott, BC Cancer, Vancouver, BC, Canada
- 1:55–2:10 p.m. **Molecular classification of diffuse large B-cell lymphoma**  
Bjoern Chapuy, University of Göttingen, Göttingen, Germany
- 2:10–2:25 p.m. **Microenvironmental signatures reveal biological and clinical subtypes of diffuse large B-cell lymphoma**  
Leandro C. Cerchiatti, Weill Cornell Medical College, New York, NY
- 2:25–2:55 p.m. Discussion / Q&A

### Break

2:55–3:10 p.m.

### Session 3: Towards a Better Understanding of Adolescent Young Adult Lymphoma

*Moderator: Sonali M. Smith, University of Chicago, Chicago, IL*

3:10–4:20 p.m.

Channel 1

- 3:10–3:15 p.m. Moderator Introduction

- 3:15–3:30 p.m.      **AYA lymphomas: Bridging the divide**  
Kara Kelly, Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 3:30–3:45 p.m.      **Genomics of common AYA lymphomas: Hodgkin lymphoma and primary mediastinal B-cell lymphoma**  
Lisa G. Giulino-Roth, Weill Cornell Medical College, New York, NY
- 3:45–4:00 p.m.      **Unique features of pediatric-type follicular lymphoma**  
Abner Louissaint, Massachusetts General Hospital, Boston, MA
- 4:00–4:20 p.m.      Discussion / Q&A

#### **Session 4: How Aberrant Metabolism Fuels Lymphoma**

*Moderator: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*

3:10–4:05 p.m.

Channel 2

- 3:10–3:15 p.m.      Moderator Introduction
- 3:15–3:30 p.m.      **Oncogenic Rag GTPase signaling links cellular nutrients with FL microenvironment**  
Alejo Efeyan, Spanish National Cancer Research Center, CNIO, Madrid, Spain
- 3:30–3:45 p.m.      **Metabolic control of lymphomagenesis**  
Andrew Michael Intlekofer, Memorial Sloan Kettering Cancer Center, New York, NY
- 3:45–4:05 p.m.      Discussion / Q&A

## **Tuesday, August 18**

---

#### **Session 5: New CARs and Fine-Tuning Patient Selection for Therapy**

*Moderator: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY*

10–11:20 a.m.

Channel 1

- 10–10:05 a.m.      Moderator Introduction
- 10:05–10:20 a.m.      **CARs and armored CARs: Improving CAR T cell therapy for cancer**  
Renier J. Brentjens
- 10:20–10:35 a.m.      **CAR T-cells for T-cell lymphoma**  
Maksim Mamonkin, Baylor College of Medicine, Houston, TX

10:35–10:50 a.m.      **Determinants of CAR-T outcomes: Host, tumor, and product**  
Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center,  
Houston, TX

10:50–11:20 a.m.      Discussion / Q&A

### **Break**

11:20–11:50 a.m.

### **Session 6: Biology-Based Clinical Trials: A Myth or Hope for Reality?**

*Moderator: John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia*

11:50 a.m.–1:25 p.m.

Channel 1

11:50–11:55 a.m.      Moderator Introduction

11:55 a.m.–12:10 p.m. **Can we hope for success in biologically stratified DLBCL studies?**  
Andrew John Davies, University of Southampton School of Medicine,  
Southampton, United Kingdom

12:10–12:25 p.m.      **Why good trials fail: Impact of biomarker requirement on the selection bias of study patients**  
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science,  
Rochester, MN

12:25–12:40 p.m.      **Biomarker *informed* studies in peripheral T-cell lymphoma**  
Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY

12:40–12:55 p.m.      **Precision treatment of lymphoma using genomics**  
Louis M. Staudt, National Cancer Institute, Bethesda, MD

12:55–1:25 p.m.      Discussion / Q&A

### **Break**

1:25–1:40 p.m.

### **Session 7: Hacking the Lymphoma Epigenome to Create Better Therapies**

*Moderator: Ari M. Melnick, Weill Cornell Medical College, New York, NY*

1:40–3:15 p.m.

Channel 1

1:40–1:45 p.m.      Moderator Introduction

1:45–2:00 p.m.      **The role of EZH2 gain-of-function mutations in lymphoma**  
Wendy Béguelin, Weill Cornell Medical College, New York, NY

- 2:00–2:15 p.m.      **Cooperative epigenetic interactions in normal and transformed germinal center B cells**  
 Laura Pasqualucci, New York Presbyterian Hospital Herbert Irving Comprehensive Cancer Center, New York, NY
- 2:15–2:30 p.m.      **CREBBP: Not all mutations are created equal**  
 Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
- 2:30–2:45 p.m.      **What do the results from the trials tell us?**  
 Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom
- 2:45–3:15 p.m.      Discussion / Q&A

**Break**

3:15–3:30 p.m.

**Session 8: Cancer Health Disparities in Lymphoma: How Do We Improve Outcomes?**

*Moderator: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX*

3:30–4:40 p.m.

Channel 1

- 3:30–3:35 p.m.      Moderator Introduction
- 3:35–3:50 p.m.      **Risk disparities in lymphoid cancers: What we know and what we don't**  
 Wendy Cozen, USC Norris Comprehensive Cancer Center, Los Angeles, CA
- 3:50–4:05 p.m.      **Disparities in late effects incidence among adolescent and young survivors of lymphoma**  
 Theresa H. M. Keegan, University of California Davis, Sacramento, CA
- 4:05–4:20 p.m.      **Genome-estimated African ancestry is associated with distinct tumor mutations and poorer survival in patients with diffuse large B-cell lymphoma**  
 Christopher R. Flowers
- 4:20–4:40 p.m.      Discussion / Q&A

**Session 9: Hitting Back at MYC/BCL2 Lymphomas**

*Moderator: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA*

3:30–4:40 p.m.

Channel 2

- 3:30–3:35 p.m.      Moderator Introduction
- 3:35–3:50 p.m.      **Targeting MYC deregulation in cancer**  
 Dinis Calado, The Francis Crick Institute, London, United Kingdom

- 3:50–4:05 p.m.      **Modeling and targeting double-hit lymphoma**  
Bruno Amati, European Institute of Oncology, Milan, Italy
- 4:05–4:20 p.m.      **Targeting BCL-2 with venetoclax**  
Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, MA
- 4:20–4:40 p.m.      Discussion / Q&A

## Wednesday, August 19

---

### Session 10: Dissecting Lymphoma Cell by Cell: A Dynamic Tale

*Moderator: Kojo Elenitoba-Johnson, University of Pennsylvania School of Medicine, Philadelphia, PA*

10–11:35 a.m.

Channel 1

- 10–10:05 a.m.      Moderator Introduction
- 10:05–10:20 a.m.      **Single-cell delineation of clonal variation and cellular tumor microenvironmental interactions in follicular lymphoma**  
Hanlee P. Ji, Stanford University, Stanford, CA
- 10:20–10:35 a.m.      **Pathology from the atomic scale on up**  
Garry P. Nolan, Stanford Hospital, Stanford, CA
- 10:35–10:50 a.m.      **Follicular lymphoma dynamics through single-cell analysis**  
Bertrand Nadel, Centre d'Immunologie de Marseille-Luminy, Marseille, France
- 10:50–11:05 a.m.      **Characterizing the tumor ecosystem in follicular lymphoma by CyTOF**  
Andrew P. Weng, BC Cancer, Vancouver, BC, Canada
- 11:05–11:35 a.m.      Discussion / Q&A

### Break

11:35–11:50 a.m.

### Session 11: Can We Find and Destroy Lymphoma Precursor Cells?

*Moderator: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX*

11:50 a.m.–1:25 p.m.

Channel 1

- 11:50–11:55 a.m.      Moderator Introduction
- 11:55 a.m.–12:10 p.m. **Tracking precursor stages of follicular lymphoma development**

Sandrine Roulland, Centre d'Immunologie de Marseille-Luminy, Marseille, France

- 12:10–12:25 p.m. **Defining lymphoma reservoirs: Clues from the genomics**  
Jessica Okosun, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
- 12:25–12:40 p.m. **Investigating malignant transformation in Waldenstrom's Macroglobulinemia**  
Zachary R. Hunter, Dana-Farber Cancer Institute, Boston, MA
- 12:40–12:55 p.m. **Defining precursors in low-grade lymphomas that seed second lymphomas**  
David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
- 12:55–1:25 p.m. Discussion / Q&A

### **Break**

1:25–1:40 p.m.

### **Session 12: Using Liquid Biopsies for Real-Time Monitoring of Lymphoma Biology and Clinical Decision-Making**

*Moderator: David W. Scott, BC Cancer, Vancouver, BC, Canada*

1:40–3:15 p.m.

Channel 1

- 1:40–1:45 p.m. Moderator Introduction
- 1:45–2:00 p.m. **Approaches for personalized medicine in lymphoma through liquid biopsies**  
David M. Kurtz, Stanford University, Stanford, CA
- 2:00–2:15 p.m. **Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA**  
Ryan D. Morin, Simon Fraser University, Burnaby, BC, Canada
- 2:15–2:30 p.m. **Qualification and quantification of lymphoma under therapy by ctDNA analysis**  
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland
- 2:30–2:45 p.m. **ctDNA in indolent lymphoid cancers treated with targeted therapies**  
Constantine S. Tam, St. Vincent's Hospital Sydney, East Melbourne, Australia
- 2:45–3:15 p.m. Discussion / Q&A

### **Break**

3:15–3:30 p.m.

### **Session 13: Preclinical Models: How to Best Predict Therapeutic Response**

*Moderator: Teresa Palomero, Columbia University, New York, NY*

3:30–4:55 p.m.  
Channel 1

- 3:30–3:35 p.m. Moderator Introduction
- 3:35–3:50 p.m. **Developing preclinical models for peripheral T-cell lymphomas**  
Teresa Palomero
- 3:50–4:05 p.m. **Molecular and genetic profiling in canine lymphoma unravels targets for the human counterpart**  
Luca Aresu, University of Turin, Turin, Italy
- 4:05–4:20 p.m. **Patient-derived tumor xenograft of human lymphomas**  
Giorgio Inghirami, Weill Cornell Medicine, New York, NY
- 4:20–4:35 p.m. **Lymphoma organoids to study cooperative signaling and therapeutic resistance in human DLBCLs**  
Ankur Singh, Georgia Institute of Technology, Atlanta, GA
- 4:35–4:55 p.m. Discussion / Q&A

**Session 14: Understanding and Targeting Aberrant Receptor Signaling in Lymphoma**

*Moderator: Louis M. Staudt, National Cancer Institute, Bethesda, MD*

3:30–4:40 p.m.  
Channel 2

- 3:30–3:35 p.m. Moderator Introduction
- 3:35–3:50 p.m. **MALT1 targeting for B-cell lymphomas**  
Lorena Fontan, Weill Cornell Medical College, New York, NY
- 3:50–4:05 p.m. **Tracking MYC-lymphoma evolution in vivo: Role of the B-cell receptor**  
Stefano Casola, The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
- 4:05–4:20 p.m. **B-cell receptor– and co-receptor–driven metabolism reprogramming**  
Benjamin Gewurz, Brigham & Women’s Hospital, Boston, MA
- 4:20–4:40 p.m. Discussion / Q&A

**Break**

4:55–5:10 p.m.

**Keynote Address and Closing Remarks**

5:10–6 p.m.  
Channel 1



- 5:10 p.m. Keynote Introduction  
Ari M. Melnick, Weill Cornell Medical College, New York, NY
- 5:10–5:35 p.m. **Cellular and molecular control of germinal center B-cell selection**  
Gabriel Victora, The Rockefeller University, New York, NY
- 5:35–5:50 p.m. Discussion / Q&A
- 5:50–6:00 p.m. Closing Remarks